본문 바로가기
KERD
논문KCI 등재

Guidelines for the Use of Botulinum Toxin in Otolaryngology From the Korean Society of Laryngology, Phoniatrics and Logopedics Guideline Task Force

이승원|권민수|이동근|이영찬|우주현|최승호|류창환|이길준|홍용태|변형권|반명진
대한이비인후과학회 (Korean Society of Otorhinolaryngology-Head and Neck Surgery)|2023.11|Clinical and Experimental Otorhinolaryngology|제16권 제4호|pp. 291-307|DOI https://doi.org/10.21053/ceo.2023.00458

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

Salivary GlandDysphoniaBotulinum ToxinsVocal Cord ParalysisEsophageal SphincterUpperCricopharyngeal Dysfunction

초록

The Korean Society of Laryngology, Phoniatrics and Logopedics created a task force to establish clinical practice guidelinesfor the use of botulinum toxin (BT) in otolaryngology. We selected 10 disease categories: spasmodic dysphonia, essentialvocal tremor, vocal fold granuloma, bilateral vocal fold paralysis, Frey’s syndrome, sialocele, sialorrhea, cricopharyngealdysfunction, chronic sialadenitis, and first bite syndrome. To retrieve all relevant papers, we searched the CORE databaseswith predefined search strategies, including Medline (PubMed), Embase, the Cochrane Library, and KoreaMed. The com-mittee reported 13 final recommendations with detailed evidence profiles. The guidelines are primarily aimed at all clini-cians applying BT to the head and neck area. In addition, the guidelines aim to promote an improved understanding of thesafe and effective use of BT by policymakers and counselors, as well as in patients scheduled to receive BT injections.

Abstract

The Korean Society of Laryngology, Phoniatrics and Logopedics created a task force to establish clinical practice guidelinesfor the use of botulinum toxin (BT) in otolaryngology. We selected 10 disease categories: spasmodic dysphonia, essentialvocal tremor, vocal fold granuloma, bilateral vocal fold paralysis, Frey’s syndrome, sialocele, sialorrhea, cricopharyngealdysfunction, chronic sialadenitis, and first bite syndrome. To retrieve all relevant papers, we searched the CORE databaseswith predefined search strategies, including Medline (PubMed), Embase, the Cochrane Library, and KoreaMed. The com-mittee reported 13 final recommendations with detailed evidence profiles. The guidelines are primarily aimed at all clini-cians applying BT to the head and neck area. In addition, the guidelines aim to promote an improved understanding of thesafe and effective use of BT by policymakers and counselors, as well as in patients scheduled to receive BT injections.

참고문헌 (70)

  1. Hyodo M, "Botulinum toxin therapy for spasmodic dysphonia in Japan : the history and an update", Toxins(Basel), 14(7), pp.451~ (2022)
  2. Newland DP, "Voice tremor and botulinum neurotoxin therapy : a contemporary review", Toxins(Basel), 14(11), pp.773~ (2022)
  3. Schneider I, "Treatment of dysfunction of the cricopharyngeal muscle with botulinum A toxin : introduction of a new, noninvasive method", Ann Otol Rhinol Laryngol, 103(1), pp.31~35 (1994)
  4. Nasri S, "Treatment of vocal fold granuloma using botulinum toxin type A", Laryngoscope, 105(6), pp.585~588 (1995)
  5. Drobik C, "Frey’s syndrome : treatment with botulinum toxin", Acta Otolaryngol, 115(3), pp.459~461 (1995)
  6. Jost WH, "Therapy of sialorrhea with botulinum neurotoxin", Neurol Ther, 8(2), pp.273~288 (2019)
  7. Yike Li, "Current Treatment Options for Bilateral Vocal Fold Paralysis: A State-of-the-Art Review", Clinical and Experimental Otorhinolaryngology, 10(3), pp.203~212 (2017), 대한이비인후과학회[DOI]
  8. Vargas H, "A pilot study evaluating the treatment of postparotidectomy sialoceles with botulinum toxin type A", Arch Otolaryngol Head Neck Surg, 126(3), pp.421~424 (2000)
  9. Strohl MP, "Botulinum toxin for chronic parotid sialadenitis : a case series and systematic review", Laryngoscope Investig Otolaryngol, 6(3), pp.404~413 (2021)
  10. Ali MJ, "Botulinum toxin in the treatment of first bite syndrome", Otolaryngol Head Neck Surg, 139(5), pp.742~743 (2008)
  11. Lee BJ, "Novel treatment of first bite syndrome using botulinum toxin type A", Head Neck, 31(8), pp.989~993 (2009)
  12. Chiu SY, "An update on botulinum toxin in neurology", Neurol Clin, 39(1), pp.209~229 (2021)
  13. Anandan C, "Botulinum toxin in movement disorders : an update", Toxins(Basel), 13(1), pp.42~ (2021)
  14. Jankovic J, "Botulinum toxin : state of the art", Mov Disord, 32(8), pp.1131~1138 (2017)
  15. Smith TJ, "Historical and current perspectives on Clostridium botulinum diversity", Res Microbiol, 166(4), pp.290~302 (2015)
  16. Oh HM, "Botulinum toxin for neuropathic pain : a review of the literature", Toxins(Basel), 7(8), pp.3127~3154 (2015)
  17. Qerama E, "The role of botulinum toxin in management of pain : an evidence-based review", Curr Opin Anaesthesiol, 23(5), pp.602~610 (2010)
  18. Kim JE, "The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines", Plast Reconstr Surg, 135(3), pp.732~741 (2015)
  19. Cha W, "Liquid-type botulinum toxin type A in adductor spasmodic dysphonia : a prospective pilot study", J Voice, 31(3), pp.378~ (2017)
  20. Scaglione F, "Conversion ratio between Botox(R), Dysport(R), and Xeomin(R)in clinical practice", Toxins(Basel), 8(3), pp.65~ (2016)
  21. (2018)[URL]
  22. Cote TR, "Botulinum toxin type A injections : adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases", J Am Acad Dermatol, 53(3), pp.407~415 (2005)
  23. Lee SW, "Botulinum toxin for other head and neck lesions", J Korean Soc Laryngol Phoniatr Logop, 23(2), pp.104~110 (2012)
  24. Samizadeh S, "Botulinum neurotoxin formulations : overcoming the confusion", Clin Cosmet Investig Dermatol, 11, pp.273~287 (2018)
  25. Kim SY, "Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity", J Clin Epidemiol, 66(4), pp.408~414 (2013)
  26. Shea BJ, "Development of AMSTAR : a measurement tool to assess the methodological quality of systematic reviews", BMC Med Res Methodol, 7, pp.10~ (2007)
  27. Blitzer A, "Botulinum toxin management of spasmodic dysphonia(laryngeal dystonia) : a 12-year experience in more than 900 patients", Laryngoscope, 108(10), pp.1435~1441 (1998)
  28. Watts C, "Botulinum toxin for treating spasmodic dysphonia(laryngeal dystonia) : a systematic Cochrane review", Clin Rehabil, 20(2), pp.112~122 (2006)
  29. Boutsen F, "Botox treatment in adductor spasmodic dysphonia : a meta-analysis", J Speech Lang Hear Res, 45(3), pp.469~481 (2002)
  30. Troung DD, "Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia", Laryngoscope, 101(6 Pt 1), pp.630~634 (1991)
  31. Hyodo M, "Botulinum toxin injection into the intrinsic laryngeal muscles to treat spasmodic dysphonia : a multicenter, placebo-controlled, randomized, double-blinded, parallel-group comparison", open-label clinical trial, 2021, pp.28(5), 1548~1556
  32. Faham M, "Quality of life after botulinum toxin injection in patients with adductor spasmodic dysphonia; a systematic review and meta-analysis", J Voice, 35(2), pp.271~283 (2021)
  33. Courey MS, "Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin", Ann Otol Rhinol Laryngol, 109(9), pp.819~822 (2000)
  34. van Esch BF, "Effect of botulinum toxin and surgery among spasmodic dysphonia patients", Otolaryngol Head Neck Surg, 156(2), pp.238~254 (2017)
  35. Dharia I, "Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia in a large cohort", Laryngoscope, 130(11), pp.2659~2662 (2020)
  36. Adams SG, "Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia", J Otolaryngol, 24(6), pp.345~351 (1995)
  37. Lee SJ, "Alternating unilateral versus bilateral injections of botulinum toxin for the treatment of adductor spasmodic dysphonia", Otolaryngol Head Neck Surg, 164(4), pp.815~820 (2021)
  38. Upile T, "Unilateral versus bilateral thyroarytenoid Botulinum toxin injections in adductor spasmodic dysphonia : a prospective study", Head Face Med, 5, pp.20~ (2009)
  39. Bielamowicz S, "Unilateral versus bilateral injections of botulinum toxin in patients with adductor spasmodic dysphonia", J Voice, 16(1), pp.117~123 (2002)
  40. Langeveld TP, "Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia", Ann Otol Rhinol Laryngol, 107(4), pp.280~284 (1998)
  41. Koriwchak MJ, "Alternating unilateral botulinum toxin type A(BOTOX)injections for spasmodic dysphonia", Laryngoscope, 106(12 Pt 1), pp.1476~1481 (1996)
  42. Kim JW, "Treatment efficacy of electromyography versus fiberscopy-guided botulinum toxin injection in adductor spasmodic dysphonia patients : a prospective comparative study", ScientificWorldJournal, 2014, pp.327928~ (2014)
  43. Fulmer SL, "Efficacy of laryngeal botulinum toxin injection : comparison of two techniques", Laryngoscope, 121(9), pp.1924~1928 (2011)
  44. Rosow DE, "Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia", Otolaryngol Head Neck Surg, 148(6), pp.1003~1006 (2013)
  45. Novakovic D, "Botulinum toxin treatment of adductor spasmodic dysphonia : longitudinal functional outcomes", Laryngoscope, 121(3), pp.606~612 (2011)
  46. Bielamowicz S, "Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia", Ann Otol Rhinol Laryngol, 110(5 Pt 1), pp.406~412 (2001)
  47. Woodson G, "Botulinum toxin therapy for abductor spasmodic dysphonia", J Voice, 20(1), pp.137~143 (2006)
  48. Klein AM, "Vocal outcome measures after bilateral posterior cricoarytenoid muscle botulinum toxin injections for abductor spasmodic dysphonia", Otolaryngol Head Neck Surg, 139(3), pp.421~423 (2008)
  49. Bhatia KP, "Consensus statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society", Mov Disord, 33(1), pp.75~87 (2018)
  50. Haubenberger D, "Essential tremor", N Engl J Med, 378(19), pp.1802~1810 (2018)
  51. Sulica L, "Clinical characteristics of essential voice tremor : a study of 34 cases", Laryngoscope, 120(3), pp.516~528 (2010)
  52. Guglielmino G, "Comparison of botulinum toxin and propranolol for essential and dystonic vocal tremors", Clinics(Sao Paulo), 73, pp.e87~ (2018)
  53. Sharma S, "Treatment of essential tremor : current status", Postgrad Med J, 96(1132), pp.84~93 (2020)
  54. Hertegard S, "Botulinum toxin injections for essential voice tremor", Ann Otol Rhinol Laryngol, 109(2), pp.204~209 (2000)
  55. Kaye R, "Chemodenervation of the larynx", Toxins(Basel), 9(11), pp.356~ (2017)
  56. Adler CH, "Botulinum toxin type A for treating voice tremor", Arch Neurol, 61(9), pp.1416~1420 (2004)
  57. Gurey LE, "A new paradigm for the management of essential vocal tremor with botulinum toxin", Laryngoscope, 123(10), pp.2497~2501 (2013)
  58. Orbelo DM, "Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor", J Voice, 28(1), pp.123~127 (2014)
  59. Benninger MS, "Noncosmetic uses of botulinum toxin in otolaryngology", Cleve Clin J Med, 82(11), pp.729~732 (2015)
  60. Hoffman HT, "Vocal process granuloma", Head Neck, 23(12), pp.1061~1074 (2001)
  61. Martins RH, "Treatment of laryngeal granulomas", Int Arch Otorhinolaryngol, 23(3), pp.e322~4 (2019)
  62. Shoffel-Havakuk H, "In-office procedures for the treatment of benign vocal fold lesions in the awake patient : a contemporary review", Laryngoscope, 129(9), pp.2131~2138 (2019)
  63. Rudman JR, "Assessing the utility of non-surgical treatments in the management of vocal process granulomas", J Laryngol Otol, 134(1), pp.68~73 (2020)
  64. Karkos PD, "Vocal process granulomas : a systematic review of treatment", Ann Otol Rhinol Laryngol, 123(5), pp.314~320 (2014)
  65. Yilmaz T, "Botulinum toxin a for treatment of contact granuloma", J Voice, 30(6), pp.741~743 (2016)
  66. Pham Q, "Botulinum toxin injections into the lateral cricoarytenoid muscles for vocal process granuloma", J Voice, 32(3), pp.363~366 (2018)
  67. Hamdan AL, "Interarytenoid botulinum toxin A injection for the treatment of vocal process granuloma", J Laryngol Otol, 133(12), pp.1041~1045 (2019)
  68. Fink DS, "Interarytenoid botulinum toxin injection for recalcitrant vocal process granuloma", Laryngoscope, 123(12), pp.3084~3087 (2013)
  69. Orloff LA, "Vocal fold granuloma : successful treatment with botulinum toxin", Otolaryngol Head Neck Surg, 121(4), pp.410~413 (1999)
  70. Pham J, "Botulinum toxin : helpful adjunct to early resolution of laryngeal granulomas", J Laryngol Otol, 118(10), pp.781~785 (2004)

관련 논문AI추천

보툴리눔 독소를 이용한 성대육아종과 성대결절 치료이승원대한후두음성언어의학회 · 대한후두음성언어의학회지2019 · 제30권 제2호상부 식도괄약근과 후두에서의 보툴리눔 독소의 이용이승원대한연하장애학회 · 대한연하장애학회지2015 · 제5권 제1호이비인후과 영역에서의 보툴리눔 독소의 활용강민석, 변형권대한이비인후과학회 · 대한이비인후과학회지 두경부외과학2024 · 제67권 제7호신경학적 후두질환에서 보툴리눔 독소 주입술의 최신 동향조정해대한후두음성언어의학회 · 대한후두음성언어의학회지2025 · 제36권 제2호음성 및 후두 질환에서 A형 보툴리눔 독소의 적용왕수건, 이병주, 이윤세, 장민지대한이비인후과학회 부산,울산,경남 지부회 · 임상이비인후과2012 · 제23권 제1호기능성 음성장애에서 보툴리늄 독소의 임상적 적용김한수대한후두음성언어의학회 · 대한후두음성언어의학회지2019 · 제30권 제1호

이 간행물의 다른 논문 (12건)

The Olfactory System: Basic Anatomy and Physiology for General Otorhinolaryngologists김진국, 이재서, 한선아, 조도연, Zara M. Patelpp. 308-316Endoscope-Assisted Hairline Approach for Head and Neck Masses: A Review우승훈, 송민석pp. 317-325Increased Resting-State Positron Emission Tomography Activity After Cochlear Implantation in Adult Deafened Cats오승하, 김도희, 김진수, 이선화, 박민현pp. 326-333Findings of Intravenous Gadolinium Inner Ear Magnetic Resonance Imaging in Patients With Acute Low-Tone Sensorineural Hearing Loss김이경, 서희원, 조영상, 정원호, 김형진pp. 334-341A Novel EYA1 Mutation Causing Alternative RNA Splicing in a Chinese Family With Branchio-Oto Syndrome: Implications for Molecular Diagnosis and Clinical ApplicationYongjia Chen, Shuang Mao, Xianlin Liu, Xin Peng, Jie Ling, Yong Feng, Anhai Chen, Chufeng He, Jian Song, Shuai Zhang, Mengyao Qin, Yijiang Bai, Zhili Feng, Lu Ma, Dinghua He, Lingyun Mei1pp. 342-358
원문 보기